Subgroup analyses of second-line immunotherapy trials have demonstrated that patients with NSCLC driven by EGFR or ALK mutations do not gain the same benefits from immunotherapy when given as a single agent [37]. This evidence concerns the gene ALK and non-small cell lung carcinoma.